A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

NCT07668154 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

HNSCC

Interventions

DRUG: SKB571
DRUG: Pembrolizumab
DRUG: carboplatin
DRUG: Cisplatin

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.